Sodium-glucose transporters SGLT1 and SGLT2 in equine renal, hepatic and pancreatic tissue.

ABSTRACT:

Background

Insulin dysregulation is a hallmark of equine metabolic syndrome (EMS), and in recent years, pharmacological treatment with sodium-dependent glucose transporter 2 inhibitors (SGLT2i) have shown promise in reducing the risk of hyperinsulinemia-associated laminitis in horses diagnosed with EMS. In humans and laboratory animals, this transporter protein is responsible for the majority of renal tubular glucose reabsorption, however, the presence of this and the related sodium-dependent glucose transporter 1 (SGLT1) have not yet been studied in equine kidneys. Additionally, studies in humans and laboratory animals have documented the presence of SGLT1 and SGLT2 also in hepatic and pancreatic tissue, which may explain extra-renal treatment effects of SGLT2i. Since the specific

SUBMITTER: Anger-Haal C 

PROVIDER: S-EPMC12822031 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature